University of Pittsburgh researchers have developed a novel therapeutic approach for treating microvascular obstruction (MVO) using tissue plasminogen activator (tPA) labeled microbubbles combined with ultrasound. This innovative method leverages ultrasound-targeted microbubble cavitation (UTMC) to enhance thrombolysis and restore microvascular patency, potentially improving outcomes for patients with coronary artery disease.
Activity of a tPA-loaded MB (tMB) using NHS-PEG-Biotin, as measured at 450 nm. Quantification using BCA assay showed 1.38 E-7 ug of tPA per MB.
Description
The technology involves the synthesis of tPA-labeled microbubbles designed to target and disrupt microthrombi in the microvasculature. The microbubbles are created using a lipid formulation sonicated in the presence of perfluorobutane to produce biotin-labeled lipid microbubbles. These microbubbles are then conjugated with streptavidin and biotinylated tPA, resulting in tPA-labeled microbubbles. When exposed to ultrasound, these microbubbles undergo cavitation, leading to mechanical disruption of thrombi and enhanced enzymatic thrombolysis from the locally delivered tPA. This dual-action approach aims to improve coronary flow and reduce complications associated with MVO during percutaneous coronary intervention (PCI).
Applications
• Treatment of microvascular obstruction in coronary artery disease
• Enhancing thrombolysis during percutaneous coronary intervention
• Potential use in other vascular diseases involving microthrombi
Advantages
This technology is the first documented attachment of tPA to the surface of a lipid microbubble using a covalent bond, allowing for targeted delivery to thrombi. The combination of ultrasound-mediated cavitation and enzymatic thrombolysis provides a synergistic effect, enhancing the efficacy of thrombus disruption. This approach addresses the limitations of current mechanical and pharmacological therapies, offering a novel solution for improving microvascular patency and patient outcomes.
Invention Readiness
The technology has been validated through in vitro studies, demonstrating the successful synthesis and functionality of tPA-labeled microbubbles. Researchers have shown that these microbubbles can effectively target and disrupt thrombi when exposed to ultrasound, supporting the potential for clinical application.
IP Status
https://patents.google.com/patent/US11793863B2
